Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson COVID-19 vaccine authorized for use in U.K.

The Johnson & Johnson COVID-19 vaccine has been authorized for emergency use by the U.K. medicines regulator.

Johnson & Johnson COVID-19 vaccine authorized for use in the U.K.

The single-shot coronavirus vaccine from Johnson & Johnson (NYSE: JNJ) has been approved for use in the U.K., making it the fourth vaccine to be used in the country to protect against COVID-19. The vaccine was 85% effective in stopping severe illness from COVID-19 in the clinical trials.

Johnson & Johnson's COVID-19 Shot Approved In UK

The British government has secured 20 million doses of the Janssen vaccine to be rolled out nationwide.

UK approves Janssen single-dose Covid vaccine for use

The UK's medicines regulator has approved the Johnson & Johnson single-dose coronavirus vaccine for use in the country.   Health Secretary Matt Hancock said the approval is "a further boost to the UK's hugely successful vaccination programme."

The UK has approved Johnson & Johnson's single-dose coronavirus vaccine

AstraZeneca

Novavax

Several of these vaccine makers face challenges.

COVID Vaccine Update: Where J&J, AstraZeneca, Novavax, and Sinovac Stand Now

The Food and Drug Administration and vaccine maker Johnson & Johnson expect to announce as early as Friday that contamination problems at a COVID-19 vaccine plant in Baltimore are resolved, clearing the way for millions more doses to become available.

The Wall Street Journal: FDA, J&J set to announce Baltimore vaccine plant ready to reopen

American Tower

Bristol-Myers

British American Tobacco

Enbridge

Altria

Philip Morris

Invesco QQQ

S&P Global

SPDR S&P 500 ETF Trust

AT&T

When someone gives you a choice: ask if you can have both? Inflation might be transitory, it might also be here to stay.

Become Inflation Proof: Buy These 4 High Quality Dividend Growth Stocks

German scientists at Goethe University have claimed to know why some COVID-19 vaccines can cause blood clots. AstraZeneca PLC (LON:AZN) and Johnson & Johnson (NYSE:JNJ) have both developed DNA-based formulations that have been linked to very rare cases of blood clots, some of which caused death.

German scientists claim to know why AstraZeneca, Johnson & Johnson COVID-19 vaccines cause blood clots

BioNTech SE

Pfizer

Moderna

On Tuesday, Reuters reported that the EU is targeting more than 1 billion COVID-19 shots by September. This is a huge figure considering that since the vaccine roll-outs began earlier this year, only 266 million vaccinations have been administered in the European Union.

Best COVID-19 vaccine stock to buy in June: Pfizer

Belgium is suspending vaccinations with Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine for people under the age of 41 following the death of a woman from severe side effects after receiving the shot. "The Inter-ministerial conference has decided to temporarily administer Janssen's vaccine to the general population from the age of 41 years, pending a more detailed benefit-risk analysis by the EMA," said a statement issued by Belgium's federal health minister and seven regional counterparts.

Belgium Stops JNJ COVID-19 Vaccine For Under 41 Years After One Death: Reuters

Franklin Resources

Lowe's

Annaly Capital

People's United Financial

Telefonica SA

These dividend stocks are excellent picks, whether you're looking for growth, fundamentals, strong tailwinds or inflation protection. The post 7 Top Dividend Stocks Trading at a Discount Worth Snapping Up appeared first on InvestorPlace.

7 Top Dividend Stocks Trading at a Discount Worth Snapping Up

Tesla

Together, an exciting electric vehicle manufacturer and healthcare giant can help investors protect their portfolios from extreme volatility.

2 Smart Stocks to Pick During a Market Correction

Johnson & Johnson is a globally diversified company with businesses in Consumer Health, Pharmaceuticals and Medical Devices. Despite that, investors should know that its Pharmaceutical segment drives most of the company's revenue and profits.

Johnson & Johnson: Well-Known Brand, But Where's The Edge?

J&J's (JNJ) oral multiple sclerosis drug, Ponvory, receives approval in Europe after demonstrating superior efficacy in reducing annual relapses compared to Sanofi's Aubagio in clinical studies.

J&J's (JNJ) Multiple Sclerosis Drug Ponvory Gets EU Approval

JNJ is a retiree favorite given its Dividend King status and 59-year dividend growth streak. That said, it isn't right for everyone.

Why You Shouldn't Buy Johnson & Johnson

This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?

Is Johnson & Johnson a Buy for Summer 2021?

NEW BRUNSWICK, N.J., May 24, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today it will host an Environmental, Social and Governance (ESG) Investor Update Webcast at 8:00 a.m.

Johnson & Johnson to Host Live ESG Investor Update Webcast

Eli Lilly

Capital is flowing once more into healthcare stocks. These companies are three of the best components of the sector for investors to buy now.

3 Healthcare Stocks to Buy as the Sector Breaks Out

The European Commission has approved Janssen's, a unit of Johnson & Johnson (NYSE: JNJ) Ponvory (ponesimod), to treat adult patients with relapsing multiple sclerosis. The EC approval of ponesimod is based on data from the Phase 3 OPTIMUM trial that met the primary endpoint of annualized relapse rate (ARR), with a rate reduction of 30.5% compared with teriflunomide.

Janssen's Multiple Sclerosis Treatment Scores European Approval

With the FDA nod, J&J's (JNJ) Rybrevant becomes the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that targets EGFR exon 20 insertion mutations.

J&J's (JNJ) Amivantamab Gets FDA Nod for Rare Lung Cancer

The Janssen Pharmaceutical Companies, a unit of Johnson & Johnson (NYSE: JNJ), announced efficacy and safety data for Stelara (ustekinumab) in Crohn's disease (CD) and ulcerative colitis (UC), including data from the SEAVUE study, a head-to-head study of biologic therapies. Data were presented at the Clinical Science Late-Breaking Abstract Plenary session.

JNJ's Stelara Fails to Beat AbbVie's Humira In Crohn's Disease Patients

Apple

Abbott Labs

Ameriprise Financial

Air Products and Chemicals

Cincinnati Financial

Lumen Technologies

Medtronic

Microsoft

Starbucks

Total

Texas Instruments

Visa

Forecasting the income provided from a dividend growth portfolio has proven remarkably accurate, regardless of tweaks to investing philosophy. Long range predictions of an individual stock price is akin to fortune telling, yet in aggregate, the stock market increases with consistency over time.

News for Johnson & Johnson Stock (JNJ)